Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 306

This Paper With 11 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJP-12-1_002

تاریخ نمایه سازی: 1 مهر 1398

Abstract:

Background and Objective:Determination of HER2 gene is crucial in breast carcinoma management and prognosis, as HER2 alterations are linked to a shorter disease-free period, overall survival and resistance to tamoxifen anti-estrogen therapy and other chemotherapy regimens, regardless of the nodal or hormone receptor status. This study aimed to estimate HER2 gene status of infiltrative mammary cancer cases with immunohistochemically equivocal (2+) score using Silver DNA in Situ Hybridization(SISH) technique and to investigate its association with clinicopathological variables. Methods: The study included 52 formalin-fixed paraffin embedded tissue blocks from female patients with invasive breast carcinoma with score of 2+ (equivocal) HER2 immunohistochemistry. All cases were studied by silver DNA in situ hybridization technique (SISH) for the determination of the amplified HER2 DNA. Results: TheSISH technique showed that HER2 gene was not amplified in 33 cases out of 52 (63.5%); while the rest of 19 cases (36.5%) revealed amplified gene status.According to age, HER2 gene status reported non-significant difference in the age groups between cases with amplified and non-amplified gene status (P=0.173). There was a significant negative association between positive Estrogen (ER) and Progesterone (PR) status and HER2 gene amplification (P= 0.002 and 0.017, respectively). Conclusion: More than half of breast carcinoma cases with equivocal HER2 immunoreactivity showed non-amplified gene status; this needs to be considered by oncologists in their management planning of breast cancer. Amplified HER2 gene is significantly associated with negative ER and PR status that affects patients’ management protocols and future outcome of the disease.

Authors

Zaidoon A. Musa

Al-Emamain Al-Kadhimain Medical City, Baghdad, Iraq

Ban J. Qasim

Dept. of Pathology and Forensic medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq

A.Wahab A.K. Al Shaikhly

Dept. of pharmacy (Dean)/ Al Rasheed University College, Baghdad, Iraq

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. Correlation of ...
  • Sińczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, Okoń K, Stachura J. ...
  • Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, ...
  • Ji Y, Sheng L, Du X, Qiu G, Chen B, ...
  • Jang JS, Jang EJ, Park J. HER2 expression in breast ...
  • Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, ...
  • Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: ...
  • Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, ...
  • Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a ...
  • Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, ...
  • Lal P, Tan LK, Chen B. Correlation of HER-2 status ...
  • Liu C, Zhang H, Shuang C, Lu Y, Jin F, ...
  • Hanley K, Wang J, Bourne P, Yang Q, Gao AC, ...
  • Lee AH, Key HP, Bell JA, Hodi Z, Ellis IO. ...
  • Chibon F, de Mascarel I, Sierankowski G, Brouste V, Bonnefoi ...
  • Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, ...
  • Payandeh M, Sadeghi M , Sadeghi E, koohian AK. Comparison ...
  • Wang B, Wang X, Zou Y. Association between hormone receptors ...
  • Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, ...
  • Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, ...
  • Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, ...
  • Zhang H, Ren G, Wang X, Zhao J, Yao H, ...
  • Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, ...
  • Russell KS, Hung MC. Transcriptional repres­sion of the neu protooncogene ...
  • Donegan WL. Tumor-related prognostic factors for breast cancer. Ca Cancer ...
  • Prati R, Apple SK, He J, Gornbein JA, Chang HR. ...
  • Ansquer Y, Mandelbrot L, Lehy T, Salomon L, Dhainaut C, ...
  • Ariga R, Zarif A, Korasick J, Reddy V, Siziopicou K ...
  • Carbone A, Botti G, Gloghini A, Simone G, Truini M, ...
  • Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, ...
  • Kang J, Kwon GY, Lee Y, Gong G. Comparison of ...
  • Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and ...
  • Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, ...
  • Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization ...
  • Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of ...
  • نمایش کامل مراجع